Mood and cognition in leucine-rich repeat kinase 2 G2019S Parkinson's disease.
Mood and cognition in leucine-rich repeat kinase 2 G2019S Parkinson's disease.
复制标题
富含亮氨酸重复激酶 2 G2019S 帕金森病的情绪和认知。
DOI：
10.1002/mds.23746
复制
发表时间：
2011
期刊：
影响因子：
--
通讯作者：
Bressman,Susan
中科院分区：
文献类型：
--
作者：
Shanker,Vicki;Groves,Mark;Heiman,Gary;Palmese,Christina;Saunders-Pullman,Rachel;Ozelius,Laurie;Raymond,Deborah;Bressman,Susan
德系犹太人帕金森病中富含亮氨酸重复激酶 G2019S 突变的行为和认知特征尚未得到很好的描述；因此，我们试图通过半结构化精神病学访谈和神经心理学测试来更系统地描述这些特征。将 21 名具有富含亮氨酸重复激酶 G2019S 突变的德系犹太患者与年龄和性别匹配的无突变帕金森病德系犹太患者进行了比较。尽管突变携带者的情感障碍总体发生率并不更高，但根据精神障碍诊断和统计手册-IV 的结构化临床访谈确定，突变携带者患病前情感障碍的风险增加了 6 倍（比值比，6.0；P= .10）。有趣的是，我们鉴定了 2 名患有双相情感障碍的富含亮氨酸重复激酶携带者；没有突变阴性受试者有此诊断。霍普金斯言语学习测试（修订版）、线方向判断和额叶评估组的表现与之前的报告一致，组间没有差异。研究结果表明，病前情绪障碍与富含亮氨酸重复激酶帕金森病之间可能存在关联，值得进一步评估。 © 2011 运动障碍协会
The behavioral and cognitive features of the leucine‐rich repeat kinase G2019S mutation in Parkinson's disease in the Ashkenazi Jewish population are not well described; therefore, we sought to more systematically characterize these features using a semistructured psychiatric interview and neuropsychological testing. Twenty‐one Ashkenazi Jewish patients having the leucine‐rich repeat kinase G2019S mutation were compared with age‐ and sex‐matched Ashkenazi Jewish patients with Parkinson's disease without mutations. Although overall rates of affective disorders were not greater in mutation carriers, the carriers exhibited a 6‐fold increased risk of premorbid affective disorders (odds ratio, 6.0;P= .10), as determined by the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders–IV. Of interest, we identified 2 leucine‐rich repeat kinase carriers with bipolar disorder; no mutation‐negative subjects had this diagnosis. Performance on the Hopkins Verbal Learning Test–Revised, Judgment of Line Orientation, and Frontal Assessment Battery was consistent with previous reports and did not differ between groups. Study findings suggest a possible association between premorbid mood disorders and leucine‐rich repeat kinase Parkinson's disease, warranting further evaluation. © 2011 Movement Disorder Society